These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 29489874)

  • 21. Role of trough to peak efficacy in the evaluation of antihypertensive therapy.
    Meredith PA
    J Hypertens Suppl; 1998 Jan; 16(1):S59-64. PubMed ID: 9534099
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Complementary and alternative medicine for major depressive disorder: a meta-analysis of patient characteristics, placebo-response rates, and treatment outcomes relative to standard antidepressants.
    Freeman MP; Mischoulon D; Tedeschini E; Goodness T; Cohen LS; Fava M; Papakostas GI
    J Clin Psychiatry; 2010 Jun; 71(6):682-8. PubMed ID: 20573327
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Short-term antihypertensive efficacy of perindopril according to clinical profile of 3,188 patients: A meta-analysis.
    Gasowski J; Wilkins A; Drzewoski J; Kłoś J; Gaciong Z; Kabat M; Grodzicki T
    Cardiol J; 2010; 17(3):259-66. PubMed ID: 20535716
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Safety of placebo controls in pediatric hypertension trials.
    Smith PB; Li JS; Murphy MD; Califf RM; Benjamin DK
    Hypertension; 2008 Apr; 51(4):829-33. PubMed ID: 18285612
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety of nebivolol and valsartan as fixed-dose combination in hypertension: a randomised, multicentre study.
    Giles TD; Weber MA; Basile J; Gradman AH; Bharucha DB; Chen W; Pattathil M;
    Lancet; 2014 May; 383(9932):1889-98. PubMed ID: 24881993
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Research design features and patient characteristics associated with the outcome of antidepressant clinical trials.
    Khan A; Kolts RL; Thase ME; Krishnan KR; Brown W
    Am J Psychiatry; 2004 Nov; 161(11):2045-9. PubMed ID: 15514405
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Safety and efficacy of vardenafil, a selective phosphodiesterase 5 inhibitor, in patients with erectile dysfunction and arterial hypertension treated with multiple antihypertensives.
    van Ahlen H; Wahle K; Kupper W; Yassin A; Reblin T; Neureither M
    J Sex Med; 2005 Nov; 2(6):856-64. PubMed ID: 16422810
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Efficacy and tolerability of nebivolol monotherapy by baseline systolic blood pressure: a retrospective analysis of pooled data from two multicenter, 12-week, randomized, double-blind, placebo-controlled, parallel-group, dose-ranging studies in patients with mild to moderate essential hypertension.
    Germino FW
    Clin Ther; 2009 Sep; 31(9):1946-56. PubMed ID: 19843484
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Clevidipine: a review of its use in the management of acute hypertension.
    Deeks ED; Keating GM; Keam SJ
    Am J Cardiovasc Drugs; 2009; 9(2):117-34. PubMed ID: 19331440
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Antihypertensive medication and their impact on cancer incidence: a mixed treatment comparison meta-analysis of randomized controlled trials.
    Coleman CI; Baker WL; Kluger J; White CM
    J Hypertens; 2008 Apr; 26(4):622-9. PubMed ID: 18327066
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Sample size and cost analysis for pulmonary arterial hypertension drug trials using various imaging modalities to assess right ventricular size and function end points.
    Addetia K; Bhave NM; Tabit CE; Gomberg-Maitland M; Freed BH; Dill KE; Lang RM; Mor-Avi V; Patel AR
    Circ Cardiovasc Imaging; 2014 Jan; 7(1):115-24. PubMed ID: 24192452
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Health outcomes associated with various antihypertensive therapies used as first-line agents: a network meta-analysis.
    Psaty BM; Lumley T; Furberg CD; Schellenbaum G; Pahor M; Alderman MH; Weiss NS
    JAMA; 2003 May; 289(19):2534-44. PubMed ID: 12759325
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Individualizing hypertension treatment with impedance cardiography: a meta-analysis of published trials.
    Ferrario CM; Flack JM; Strobeck JE; Smits G; Peters C
    Ther Adv Cardiovasc Dis; 2010 Feb; 4(1):5-16. PubMed ID: 20042450
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Antihypertensive efficacy and tolerability of irbesartan/hydrochlorothiazide in hypertensive patients stratified by body mass index and type 2 diabetes mellitus status: a post hoc subgroup analysis of the Irbesartan/HCTZ Blood Pressure Reductions in Diverse Patient Populations trial.
    Lewin AJ; Weir MR
    Clin Ther; 2008 Dec; 30(12):2354-65. PubMed ID: 19167594
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Pediatric antihypertensive trial failures: analysis of end points and dose range.
    Benjamin DK; Smith PB; Jadhav P; Gobburu JV; Murphy MD; Hasselblad V; Baker-Smith C; Califf RM; Li JS
    Hypertension; 2008 Apr; 51(4):834-40. PubMed ID: 18332283
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Some problems with antihypertensive drug studies in the context of the new guidelines.
    Rose M; McMahon FG
    Am J Hypertens; 1990 Feb; 3(2):151-5. PubMed ID: 2407266
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Oral antihypertensive trial design and analysis under the pediatric exclusivity provision.
    Pasquali SK; Sanders SP; Li JS
    Am Heart J; 2002 Oct; 144(4):608-14. PubMed ID: 12360155
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Mortality during US FDA clinical trials in patients with diabetes, hypertension, depression and schizophrenia.
    Khan A; Fahl Mar K; Gokul S; Brown WA
    World J Biol Psychiatry; 2020 Jan; 21(1):64-71. PubMed ID: 30246595
    [No Abstract]   [Full Text] [Related]  

  • 39. The application of meta-analysis in assessing racial differences in the effects of antihypertensive medication.
    Messeri P; Workman S; Saunders C; Francis C
    J Natl Med Assoc; 1997 Jul; 89(7):477-85. PubMed ID: 9220697
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Sample size re-estimation in crossover trials: application to the AIM HY-INFORM study.
    Wych J; Grayling MJ; Mander AP
    Trials; 2019 Dec; 20(1):665. PubMed ID: 31791376
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.